AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19837207 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 44
Study 19837207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16750681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 140
Study 16750681 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 140
Study 15363569 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg clomipramine
Number of subjects: 30
Study 15363569 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 30
Study 15363569 — intervention group
Group type: COMPARATOR
Intervention: paroxetine
Number of subjects: 30
Study 15363569 — intervention group
Group type: COMPARATOR
Intervention: clomipramine
Number of subjects: 30
Study 11731062 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTXA) injection
Number of subjects: 0
Study 11731062 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (control)
Number of subjects: 0
Study 9230003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B lipid complex at 5 mg/kg total dose (1 mg/kg per day for 5 days)
Number of subjects: 60
Study 9230003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B lipid complex at 10 mg/kg total dose (2 mg/kg per day for 5 days)
Number of subjects: 60
Study 9230003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B lipid complex at 15 mg/kg total dose (3 mg/kg per day for 5 days)
Number of subjects: 60
Study 8040900 — intervention group
Group type: EXPERIMENTAL
Intervention: nHuIFN-alpha
Number of subjects: 188
Study 8040900 — intervention group
Group type: COMPARATOR
Intervention: AZT
Number of subjects: 188
Study 8040900 — intervention group
Group type: COMPARATOR
Intervention: Nothing (untreated controls)
Number of subjects: 188
Study 2902812 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg kg‐1 cimetidine (groups 3 and 5)
Number of subjects: 60
Study 2902812 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2‐0.3 mg kg‐1 etomidate (groups 2 and 3)
Number of subjects: 60
Study 2902812 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐3 mg kg‐1 thiopentone (groups 1, 4, 5 and 6)
Number of subjects: 60
Study 2902812 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08 mg kg‐1 vecuronium
Number of subjects: 60
Study 2902812 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg kg‐1 ranitidine (group 6)
Number of subjects: 60
Study 2902812 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.002 mg kg‐1 fentanyl and 0.01 mg kg‐1 lormetazepam
Number of subjects: 60
Study 1218149 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin (alphaxalone and alphadolone acetate)
Number of subjects: 32
Study 1218149 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 32
Study 1218149 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium bromide
Number of subjects: 32
Study 31461123 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted mobile technology-supported intervention
Number of subjects: 6579
Study 31461123 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 6579
Study 28396303 — intervention group
Group type: EXPERIMENTAL
Intervention: SoSu‐life tool
Number of subjects: 566
Study 28396303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 566
Study 26134386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-short stem
Number of subjects: 51
Study 26134386 — intervention group
Group type: COMPARATOR
Intervention: Conventional tapered stem
Number of subjects: 51
Study 26134386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 24206640 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily
Number of subjects: 288
Study 24206640 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 288
Study 24206640 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 288
Study 24206640 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 288
Study 21884529 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) 500 mg for 3 days during the first week, followed by 500 mg per week for the next 11 weeks
Number of subjects: 60
Study 21884529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21884529 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM)
Number of subjects: 60
Study 19726140 — intervention group
Group type: EXPERIMENTAL
Intervention: Two brief Motivational Interviewing (MI) sessions
Number of subjects: 126
Study 19726140 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 126
Study 17898353 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (dopamine D(2)/D(3) antagonist)
Number of subjects: 33
Study 17898353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 15485015 — intervention group
Group type: EXPERIMENTAL
Intervention: 186Re-sulfide (64 +/- 4 MBq)
Number of subjects: 81
Study 15485015 — intervention group
Group type: COMPARATOR
Intervention: Cortivazol (Altim) 3.75 mg
Number of subjects: 81
Study 11152924 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal preparation with povidone iodine
Number of subjects: 498
Study 11152924 — intervention group
Group type: COMPARATOR
Intervention: No preparation (control)
Number of subjects: 498
Study 9766255 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rh-GH) 0.5-1 IU/day s.c., bedtime (n=8)
Number of subjects: 29
Study 9766255 — intervention group
Group type: COMPARATOR
Intervention: placebo (n=7)
Number of subjects: 29
Study 9766255 — intervention group
Group type: COMPARATOR
Intervention: rh-GH vs placebo
Number of subjects: 29
Study 9138880 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Lin's biopsy forceps
Number of subjects: 81
Study 9138880 — intervention group
Group type: COMPARATOR
Intervention: Small conventional biopsy forceps
Number of subjects: 81
Study 9138880 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Lin's grasping forceps
Number of subjects: 81
Study 3041874 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (10 ml plasma/kgbw) using a Haemonetics separator (PCS) after premedication before anaesthesia.
Number of subjects: 30
Study 3041874 — intervention group
Group type: COMPARATOR
Intervention: Control group (no plasma withdrawal) measured at identical times as the plasmapheresis group.
Number of subjects: 30
Study 29280500 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS-8
Number of subjects: 270
Study 29280500 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS-6
Number of subjects: 270
Study 29280500 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS-30
Number of subjects: 270
Study 26350489 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived stromal vascular fraction (ADSVF) injection
Number of subjects: 12
Study 24286192 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS (Levonorgestrel-impregnated intrauterine device)
Number of subjects: 170
Study 24286192 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral MPA (10 mg daily for 6 months)
Number of subjects: 170
Study 24286192 — intervention group
Group type: COMPARATOR
Intervention: Cyclic oral MPA (10 mg for 10 days per cycle for 6 months)
Number of subjects: 170
Study 24330904 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation (n = 1,046)
Number of subjects: 2081
Study 24330904 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation as monotherapy (n = 125)
Number of subjects: 2081
Study 24330904 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation as adjunctive to conventional antidepressants (n = 33)
Number of subjects: 2081
Study 24330904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1,035)
Number of subjects: 2081
Study 20957321 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone (5 mg)
Number of subjects: 180
Study 20957321 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D (500 mg calcium + 200 mg vitamin D)
Number of subjects: 180
Study 20957321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 18375891 — intervention group
Group type: EXPERIMENTAL
Intervention: darbepoetin/iron (sodium ferric gluconate 125 mg IV weekly for the first 6 weeks)
Number of subjects: 149
Study 18375891 — intervention group
Group type: COMPARATOR
Intervention: darbepoetin (no iron)
Number of subjects: 149
Study 18375891 — intervention group
Group type: EXPERIMENTAL
Intervention: darbepoetin/iron
Number of subjects: 149
Study 16753767 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (20 g/500 mL) administered via i.v. infusion for 4 consecutive days
Number of subjects: 43
Study 16753767 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 43
Study 16753767 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (in subgroup not receiving antihypertensive drugs)
Number of subjects: 43
Study 16753767 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup not receiving antihypertensive drugs)
Number of subjects: 43
Study 12820059 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 20
Study 12820059 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 20
Study 10711609 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap with tension
Number of subjects: 11
Study 10711609 — intervention group
Group type: COMPARATOR
Intervention: Flap without tension
Number of subjects: 11
Study 9554154 — intervention group
Group type: EXPERIMENTAL
Intervention: Western blot method for detecting antibodies against rotavirus proteins
Number of subjects: 45
Study 7699621 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (MTX) therapy
Number of subjects: 0
Study 7699621 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) treatment
Number of subjects: 0
Study 7699621 — intervention group
Group type: COMPARATOR
Intervention: Control sera
Number of subjects: 0
Study 7699621 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX nonresponders
Number of subjects: 0
Study 2958727 — intervention group
Group type: EXPERIMENTAL
Intervention: Maylard incision
Number of subjects: 97
Study 2958727 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel incision
Number of subjects: 97
Study 2958727 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Maylard and Pfannenstiel incisions
Number of subjects: 97
Study 29074041 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sphenopalatine ganglion block with lidocaine 2%
Number of subjects: 33
Study 29074041 — intervention group
Group type: COMPARATOR
Intervention: Sham operation with water for injection
Number of subjects: 33
Study 27493136 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 12.5 mg b.i.d. + Metformin 1,000 mg b.i.d.
Number of subjects: 1364
Study 27493136 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 12.5 mg b.i.d. + Metformin 500 mg b.i.d.
Number of subjects: 1364
Study 27493136 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 mg b.i.d. + Metformin 1,000 mg b.i.d.
Number of subjects: 1364
Study 27493136 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 mg b.i.d. + Metformin 500 mg b.i.d.
Number of subjects: 1364
Study 27493136 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg q.d.
Number of subjects: 1364
Study 27493136 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg q.d.
Number of subjects: 1364
Study 27493136 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1,000 mg b.i.d.
Number of subjects: 1364
Study 27493136 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg b.i.d.
Number of subjects: 1364
Study 26719017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraductal stent group (IST) - custom-made segment of a T-tube placed into the bile duct, removed endoscopically 4 to 6 months later.
Number of subjects: 248
Study 26719017 — intervention group
Group type: COMPARATOR
Intervention: Control group - biliary reconstruction without an intraductal stent.
Number of subjects: 248
Study 23761968 — intervention group
Group type: EXPERIMENTAL
Intervention: RSDM+ (monthly risedronate 150 mg and cholecalciferol 30,000 IU combined in a single pill, n = 74)
Number of subjects: 150
Study 23761968 — intervention group
Group type: COMPARATOR
Intervention: RSDM (monthly risedronate 150 mg alone, n = 76)
Number of subjects: 150
Study 21401729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/Mycophenolate Mofetil (Tacr/MMF)
Number of subjects: 77
Study 21401729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/Azathioprine (Tacr/Aza)
Number of subjects: 77
Study 21401729 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Number of subjects: 77
Study 21401729 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 77
Study 18544983 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (total doses of 60 Gy with single doses of 2 Gy)
Number of subjects: 0
Study 18544983 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 0
Study 18544983 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy for pT3 tumors with positive margins
Number of subjects: 0
Study 18544983 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy for pT2 R1 tumors
Number of subjects: 0
Study 12631165 — intervention group
Group type: EXPERIMENTAL
Intervention: Appliance protecting the lesion from abrasion
Number of subjects: 10
Study 12631165 — intervention group
Group type: EXPERIMENTAL
Intervention: No appliance (unprotected)
Number of subjects: 10
Study 12631165 — intervention group
Group type: COMPARATOR
Intervention: Control (unexposed)
Number of subjects: 10
Study 11071188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglicate by inhalation
Number of subjects: 2
Study 11071188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglicate by nasal route
Number of subjects: 2
Study 8725678 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional and contrast echocardiography
Number of subjects: 20
Study 1533372 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty (BA)
Number of subjects: 30
Study 1533372 — intervention group
Group type: COMPARATOR
Intervention: Atherectomy (AT)
Number of subjects: 30
Study 3513682 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinia Melanoma Oncolysates (VMO)
Number of subjects: 48
Study 31329520 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of a proximal vessel occlusion
Number of subjects: 12048
Study 31329520 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's age
Number of subjects: 12048
Study 31329520 — intervention group
Group type: EXPERIMENTAL
Intervention: Time elapsed from symptom onset to consultation
Number of subjects: 12048
Study 28646587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-catheter for local anesthetic injection (chirochaine 0.125% w/v; 20 mL bolus before consciousness, followed by three consecutive injections of 20 mL each at 8, 16, and 24 hours post-surgery)
Number of subjects: 31
Study 26861582 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed models (Group B, n = 15)
Number of subjects: 30
Study 26861582 — intervention group
Group type: COMPARATOR
Intervention: 3D-computer models (Group A, n = 15)
Number of subjects: 30
Study 24953576 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin suppository (1g) once a day from day‐2 to day‐14 of life
Number of subjects: 50
Study 24953576 — intervention group
Group type: COMPARATOR
Intervention: No suppository
Number of subjects: 50
Study 21546099 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vardenafil 10mg
Number of subjects: 20
Study 21546099 — intervention group
Group type: COMPARATOR
Intervention: On-demand vardenafil 20mg
Number of subjects: 20
Study 20159252 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant-onset eczema
Number of subjects: 2916
Study 20159252 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema limited to infancy
Number of subjects: 2916
Study 20159252 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema persistence
Number of subjects: 2916
Study 18308653 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg weekly)
Number of subjects: 11
Study 18308653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15991553 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with Novo‐Helisen Depot allergy vaccines for 3 years
Number of subjects: 36
Study 15991553 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 36
Study 12912694 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective treatment (enucleation or eye-conserving radiotherapy)
Number of subjects: 8712
Study 12912694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size greater than 15.0 mm
Number of subjects: 8712
Study 12912694 — intervention group
Group type: EXPERIMENTAL
Intervention: Juxtapapillary tumors
Number of subjects: 8712
Study 10350559 — intervention group
Group type: EXPERIMENTAL
Intervention: Single visual stimulation
Number of subjects: 0
Study 10350559 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired visual stimulation
Number of subjects: 0
Study 8821108 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% triclosan-based handwash
Number of subjects: 5
Study 8821108 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% triclosan with 5% PI
Number of subjects: 5
Study 8821108 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate (CHG)
Number of subjects: 5
Study 8821108 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% povidone-iodine (PI)
Number of subjects: 5
Study 8821108 — intervention group
Group type: COMPARATOR
Intervention: Nonantimicrobial liquid soap
Number of subjects: 5
Study 1951474 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 16
Study 1951474 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine
Number of subjects: 16
Study 6119096 — intervention group
Group type: EXPERIMENTAL
Intervention: bunitrolol (10 mg)
Number of subjects: 9
Study 6119096 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 31145833 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-caregiver dyads who agreed on a poor prognosis
Number of subjects: 141
Study 31145833 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-caregiver dyads who disagreed regarding prognosis
Number of subjects: 141
Study 31145833 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-caregiver dyads who both believed the patient's future quality of life would be good (34%) and that the patient would live for ≥2 years (30%)
Number of subjects: 141
Study 27118716 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic cognitive training
Number of subjects: 73
Study 27118716 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 73
Study 26509682 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-Energy Techniques (MET) - 2 treatment sessions per week for 6 weeks
Number of subjects: 39
Study 26509682 — intervention group
Group type: COMPARATOR
Intervention: Control group - no intervention during the 6-week period
Number of subjects: 39
Study 23683378 — intervention group
Group type: EXPERIMENTAL
Intervention: In-plane with GPS
Number of subjects: 30
Study 23683378 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-plane with GPS
Number of subjects: 30
Study 23683378 — intervention group
Group type: COMPARATOR
Intervention: In-plane no GPS
Number of subjects: 30
Study 23683378 — intervention group
Group type: COMPARATOR
Intervention: Out-of-plane no GPS
Number of subjects: 30
Study 23683378 — intervention group
Group type: EXPERIMENTAL
Intervention: GPS technique
Number of subjects: 30
Study 21621716 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab
Number of subjects: 636
Study 21621716 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib plus placebo (control)
Number of subjects: 636
Study 19647382 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 318
Study 19647382 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 318
Study 19647382 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA/CE
Number of subjects: 318
Study 19647382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 17183623 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of disease modifying antirheumatic drugs (DMARD; COMBI)
Number of subjects: 169
Study 17183623 — intervention group
Group type: COMPARATOR
Intervention: Single DMARD (SINGLE)
Number of subjects: 169
Study 17183623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained DAS28 remission
Number of subjects: 169
Study 17183623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lost DAS28 remission after 6 months
Number of subjects: 169
Study 17183623 — intervention group
Group type: EXPERIMENTAL
Intervention: Not in remission at 6 months
Number of subjects: 169
Study 15215224 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (1000/500 mg) instilled
Number of subjects: 18
Study 15215224 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin nebulized
Number of subjects: 18
Study 15215224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin (200 mg) instilled
Number of subjects: 18
Study 15215224 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin nebulized
Number of subjects: 18
Study 12577413 — intervention group
Group type: EXPERIMENTAL
Intervention: SHSBG and CT (treated group 1)
Number of subjects: 112
Study 12577413 — intervention group
Group type: EXPERIMENTAL
Intervention: SHSBG after CT (treated group 2)
Number of subjects: 112
Study 12577413 — intervention group
Group type: COMPARATOR
Intervention: Rubidate and CT (control group 1)
Number of subjects: 112
Study 12577413 — intervention group
Group type: COMPARATOR
Intervention: Rubidate after CT (control group 2)
Number of subjects: 112
Study 9848044 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular allogenic dermis and a thin autograft
Number of subjects: 6